Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 2 2Phase 1/2 2Phase 1 2

Status

Recruiting 6Not yet recruiting 2Completed 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Neoplasms 1Hospice 1Depression 1Anxiety Disorders 1

Interventions

Cyclophosphamide 739Cisplatin 687Gemcitabine 641Bevacizumab 615Carboplatin 604Paclitaxel 600Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 360Capecitabine 342Filgrastim 333Etoposide 328Dexamethasone 312Irinotecan 309pembrolizumab 279Leucovorin 274Cetuximab 267Cytarabine 242Erlotinib Hydrochloride 231Prednisone 227Nivolumab 227Trastuzumab 225Bortezomib 221Vincristine 220Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Psilocybin × Clear all
NCT04950608 2026-02-17

PATH

Dana-Farber Cancer Institute

Phase 2 Completed
15 enrolled 26 charts
Other neoplasm

Hospice

NCT00465595 2018-07-19

Psychopharmacology of Psilocybin in Cancer Patients

Johns Hopkins University

Phase 2 Completed
56 enrolled 8 charts

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡